PReS-FINAL-2184: A randomized trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine versus prednisone plus methotrexate.

N Ruperto,A. Pistorio,S Knupp Feitosa de Oliveira,R Cuttica,A Ravelli,Michael Fischbach,Bo Magnusson,Tadej Avcin,K. Brochard,Fabrizia Corona,G. Couillault,Frank Dressler,Valeria Gerloni,Gary Sterba,F Zulian,Maria Teresa Apaz,Adriana Ivonne Céspedes Cruz,Rolando Cimaz,Claudia Bracaglia,Rik Joos,Pierre Quartier,R. Russo,Marc Tardieu,N Wulffraat,Simona Angioloni,A. Martini

PReS-FINAL-2184: A randomized trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine versus prednisone plus methotrexate.

2013

Data regarding the safety and efficacy of treatment regimens for juvenile dermatomyositis (JDM) tends to be from anecdotal, small, uncontrolled, non-randomized case series.

Keywords:

Randomized controlled trial
Juvenile dermatomyositis
Prednisone
Rheumatology
Inactive disease
Physical therapy
Methotrexate
Paediatric rheumatology
Pharmacology
Medicine
Internal medicine
new onset
Pediatrics
treatment regimen

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations